Structure Therapeutics grants options and RSUs

Structure Therapeutics Chief Commercial Officer John Joseph Berrios received equity awards on 2026-08-06.

Rhea-AI Filing Summary

Structure Therapeutics Chief Commercial Officer John Joseph Berrios received equity awards on 2026-08-06. He was granted 174,612 share options with an exercise price of 17.54 per Ordinary Share, expiring 2036-08-05, plus 140,766 restricted share units. The RSUs vest one-fourth annually from August 6, 2026, and the options vest one-fourth on that date and in thirty-six equal monthly installments thereafter, in each case subject to his continued service. Each Ordinary Share may be represented by an ADS, with each ADS representing three Ordinary Shares.

Insider Trade Summary

Grant/Award: 315,378 shares

Grant/Award 2 txns

Insider Berrios John Joseph

Role Chief Commercial Officer

Type	Security	Shares	Price	Value
Grant/Award	Share option (right to buy) F3, F4, F1	174,612	$0.00	$0.00
Grant/Award	Ordinary Shares F1, F2	140,766	$0.00	$0.00

Holdings After Transaction: Share option (right to buy) — 174,612 contracts (Direct); Ordinary Shares — 140,766 shares (Direct)

Footnotes (4)

1. F1. The Ordinary Shares of the Issuer may be represented by American Depositary Shares ("ADSs"). Each ADS represents three Ordinary Shares of the Issuer.
2. F2. Represents the grant of restricted share units ("RSUs"), each of which represents a contingent right to receive one Ordinary Share of the Issuer. The RSUs vest 1/4th annually on each anniversary of August 6, 2026, subject to Reporting Person's continued service on such dates.
3. F3. The option exercise price per share is equal to the fair market value per Ordinary Share on the grant date based on the trading price of the Issuer's ADSs.
4. F4. One-fourth of the shares vest on the first anniversary of August 6, 2026, and the remaining shares shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continued service through each such vesting date.

Key Figures

Options granted: 174,612 shares Option exercise price: 17.54 per share Option expiration: 2036-08-05 +4 more

7 metrics

Options granted 174,612 shares Share options granted to Chief Commercial Officer on 2026-08-06

Option exercise price 17.54 per share Exercise price for share options granted on 2026-08-06

Option expiration 2036-08-05 Expiration date of the granted share options

RSUs granted 140,766 units Restricted share units representing Ordinary Shares granted on 2026-08-06

ADS to Ordinary Share ratio 1 ADS : 3 Ordinary Shares Each ADS represents three Ordinary Shares of Structure Therapeutics

Options underlying shares 174,612 Ordinary Shares Ordinary Shares underlying the granted share options

RSU vesting reference date August 6, 2026 RSUs vest one-fourth annually on each anniversary of this date

Key Terms

restricted share units ("RSUs"), American Depositary Shares ("ADSs"), fair market value, vesting

4 terms

restricted share units ("RSUs") financial

"Represents the grant of restricted share units ("RSUs"), each of which represents"

American Depositary Shares ("ADSs") financial

"may be represented by American Depositary Shares ("ADSs"). Each ADS represents"

American Depositary Shares (ADSs) are U.S.-listed certificates issued by a bank that represent ownership of a specified number of a foreign company’s ordinary shares, letting U.S. investors buy and sell those interests in U.S. dollars on American markets. They matter because they make investing in overseas companies as easy as buying a domestic stock—streamlining currency, settlement, and recordkeeping—while still exposing investors to foreign-market risks like exchange rates and local regulations.

fair market value financial

"The option exercise price per share is equal to the fair market value per"

The price a willing buyer and a willing seller would agree on for an asset or security when neither is under pressure and both have access to the same information. Think of it as the market’s neutral estimate of what something is worth, like the price two neighbors would settle on for a car after comparing similar listings. Investors care because fair market value guides buying and selling decisions, tax reporting, portfolio valuation, and how accurately company assets are reflected in financial statements.

vesting financial

"One-fourth of the shares vest on the first anniversary of August 6, 2026, and the remaining"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What equity awards did GPCR grant to Chief Commercial Officer John Joseph Berrios?

John Joseph Berrios received two equity awards: 174,612 share options and 140,766 restricted share units, each linked to Ordinary Shares of Structure Therapeutics. The options carry an exercise price of 17.54 per share and expire on August 5, 2036.

How do the RSUs granted by GPCR to its Chief Commercial Officer vest?

The 140,766 RSUs vest in four annual installments. One-fourth of the restricted share units vests on each anniversary of August 6, 2026, provided John Joseph Berrios continues in service on each vesting date.

What are the terms of the share options granted by GPCR to its CCO?

The grant includes 174,612 share options with an exercise price of 17.54 per Ordinary Share and an expiration date of August 5, 2036. One-fourth vests on August 6, 2027, with the remaining shares vesting in thirty-six equal monthly installments thereafter.

How are Structure Therapeutics (GPCR) Ordinary Shares related to its ADSs?

Each American Depositary Share (ADS) represents three Ordinary Shares of Structure Therapeutics. The reported options and RSUs relate to Ordinary Shares, which may be represented in the market by ADSs using this three-to-one ratio.

Were the GPCR equity awards to John Joseph Berrios made under a Rule 10b5-1 plan?

The awards were not reported as made under a Rule 10b5-1 plan. The Rule 10b5-1 checkbox was not selected, indicating no affirmed pre-arranged trading plan for these specific equity grants.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/07/2026 - 04:09 PM Accepted by SEC EDGAR 08/07/2026 - 04:08 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Berrios John Joseph

(Last) (First) (Middle)

C/O STRUCTURE THERAPEUTICS INC.

601 GATEWAY BLVD., SUITE 900

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Structure Therapeutics Inc. [ GPCR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Commercial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/06/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares(1)	08/06/2026		A(2)		140,766	A	$0	140,766	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Share option (right to buy)	$17.54(3)	08/06/2026		A		174,612		(4)	08/05/2036	Ordinary Shares(1)	174,612	$0	174,612	D

Explanation of Responses:

1. The Ordinary Shares of the Issuer may be represented by American Depositary Shares ("ADSs"). Each ADS represents three Ordinary Shares of the Issuer.

2. Represents the grant of restricted share units ("RSUs"), each of which represents a contingent right to receive one Ordinary Share of the Issuer. The RSUs vest 1/4th annually on each anniversary of August 6, 2026, subject to Reporting Person's continued service on such dates.

3. The option exercise price per share is equal to the fair market value per Ordinary Share on the grant date based on the trading price of the Issuer's ADSs.

4. One-fourth of the shares vest on the first anniversary of August 6, 2026, and the remaining shares shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continued service through each such vesting date.

	/s/ Jun Yoon, Attorney-in-Fact	08/07/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)